FindTrial
Sign In

A clinical trial to study the frequency of genetic variations which influence the harmful levels of lead and mercury in children with the brain disorder called cerebral palsy.

Evaluation of the frequency of polymorphisms affecting lead and mercury toxicity among children with cerebral palsy.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2011/10/002036
Enrollment
250
Registered
2011-10-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Cerebral palsy

Interventions

Intervention1: not applicable: not applicable

Sponsors

Dr Y K GUPTA
Lead Sponsor
Dr Madhulika Kabra
Collaborator
Dr Sheffali Gulati
Collaborator
Dr Sundersingh Samuel S D
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Chidren aged 2-12 years with cerebral palsy attending Pediatric Neurology Outpatient department,All India Institute of Medical Sciences, NewDelhi.

Exclusion criteria

Exclusion criteria: 1.Progressive neurodegenerative disorders 2.Severe systemic illness with multiple organ dysfunctions

Design outcomes

Primary

MeasureTime frame
The blood levels of lead and mercury will increase with the increase in frequency of ALAD2 and CPOX4 variants respectively in cerebral palsy children when compared to control children.Timepoint: Not applicable—

Secondary

MeasureTime frame
The frequency of factor V Leiden and Methylenetetrahydrofolate reductase gene polymorphism C677T will increase in cerebral palsy children when compared to control children.Timepoint: Not applicable—

Countries

India

Contacts

Public ContactDr Y K GUPTA
sundersingh.samuel@gmail.com91-11-26593282

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026